Breaking News

Eli Lilly was awarded a $210M firm-fixed-price contract for 100,000 doses of Lilly's combination monoclonal antibody therapeutic treatment. Bids were solicited via the internet with one received. Work locations and funding will be determined with each order, with an estimated completion date of March 31. U.S. Army Contracting Command is the contracting activity.

Eli Lilly was awarded a $2.52B firm-fixed-price contract for Eli Lilly's combination monoclonal antibody therapeutic LY-CoV555 and LY-CoV016. Bids were solicited via the internet with one received. Work locations and funding will be determined with each order, with an estimated completion date of November 24. U.S. Army Contracting Command is the contracting activity.

The U.S. government has agreed to purchase a minimum of 100,000 doses of bamlanivimab (LY-CoV555) 700 mg and etesevimab (LY-CoV016) 1400 mg together, Eli Lilly and Company announced. Bamlanivimab and etesevimab together recently received emergency use authorization for the treatment of recently diagnosed, mild to moderate COVID-19 in patients who are at high risk of progressing to severe COVID-19 and/or hospitalization. Additionally, the National Institutes of Health recently updated the COVID-19 Treatment Guidelines to recommend the use of bamlanivimab plus etesevimab for the treatment of outpatients with mild to moderate COVID-19 who are at high risk of clinical progression. The purchase agreement is for $210M and doses will be delivered through March 31, 2021. The U.S. government will have the option to purchase up to an additional 1,100,000 doses through November 25, 2021, under the same terms as the base agreement and subject to agreement from Lilly, product availability and the medical need in the U.S. This purchase adds to the supply of neutralizing antibodies already available for use in the U.S. The government has already committed to purchase a total of 1,450,000 doses of bamlanivimab alone, which includes more than 1 million doses that have been delivered and an agreement to deliver 450,000 additional doses by March 31, 2021. The government has said it will provide neutralizing antibodies at no out-of-pocket cost to patients, although healthcare facilities may charge a fee for the product's administration. Lilly will begin shipping these additional doses immediately.

Allergan, an AbbVie company, announced that it has submitted a New Drug Application to the U.S. FDA for investigational AGN-190584 (pilocarpine 1.25%) ophthalmic solution for the treatment of presbyopia. The FDA is expected to act on the NDA by the end of 2021.